Andrea Issberner
Overview
Explore the profile of Andrea Issberner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sindi M, Hecker C, Issberner A, Ruck T, Meuth S, Albrecht P, et al.
Front Immunol
. 2023 Aug;
14:1234984.
PMID: 37638037
Introduction: In multiple sclerosis (MS), chronic disability primarily stems from axonal and neuronal degeneration, a condition resistant to conventional immunosuppressive or immunomodulatory treatments. Recent research has indicated that selective sphingosine-1-phosphate...
2.
Dietrich M, Hecker C, Martin E, Langui D, Gliem M, Stankoff B, et al.
Neurol Neuroimmunol Neuroinflamm
. 2022 Mar;
9(3).
PMID: 35354603
Background And Objectives: Siponimod is an oral, selective sphingosine-1-phosphate receptor-1/5 modulator approved for treatment of multiple sclerosis. Methods: Mouse MRI was used to investigate remyelination in the cuprizone model. We...
3.
Frenger M, Hecker C, Sindi M, Issberner A, Hartung H, Meuth S, et al.
Front Immunol
. 2021 Nov;
12:761776.
PMID: 34745138
Confocal scanning laser ophthalmoscopy (cSLO) is a non-invasive technique for real-time imaging of the retina. We developed a step-by-step protocol for the semi-automatic evaluation of myeloid cells in cSLO images...
4.
Dietrich M, Hecker C, Nasiri M, Samsam S, Issberner A, Kohne Z, et al.
Front Neurol
. 2021 Feb;
11:601628.
PMID: 33519681
While great advances have been made in the immunomodulatory treatment of multiple sclerosis (MS), there is still an unmet need for drugs with neuroprotective potential. Dimethyl fumarate (DMF) has been...
5.
Hecker C, Dietrich M, Issberner A, Hartung H, Albrecht P
J Neuroinflammation
. 2020 Jul;
17(1):216.
PMID: 32682447
Optomotor response is increasingly used in preclinical research for evaluating the visual function in rodents. However, the most suitable measuring protocol for specific scientific questions is not always established. We...
6.
Dietrich M, Koska V, Hecker C, Gottle P, Hilla A, Heskamp A, et al.
Brain
. 2020 Apr;
143(4):1127-1142.
PMID: 32293668
Chronic disability in multiple sclerosis is linked to neuroaxonal degeneration. 4-aminopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate ambulatory disability in multiple sclerosis. The presumed mode...
7.
Cruz-Herranz A, Dietrich M, Hilla A, Yiu H, Levin M, Hecker C, et al.
J Neuroinflammation
. 2019 Nov;
16(1):203.
PMID: 31684959
Background: Retinal optical coherence tomography (OCT) is a clinical and research tool in multiple sclerosis, where it has shown significant retinal nerve fiber (RNFL) and ganglion cell (RGC) layer thinning,...
8.
Dietrich M, Helling N, Hilla A, Heskamp A, Issberner A, Hildebrandt T, et al.
J Neuroinflammation
. 2018 Mar;
15(1):71.
PMID: 29514678
Background: In multiple sclerosis (MS), neurodegeneration is the main reason for chronic disability. Alpha-lipoic acid (LA) is a naturally occurring antioxidant which has recently been demonstrated to reduce the rate...
9.
Albrecht P, Henke N, Tien M, Issberner A, Bouchachia I, Maher P, et al.
Neurochem Int
. 2013 Jan;
62(5):610-9.
PMID: 23357478
Cell death in response to oxidative stress plays a role in a variety of neurodegenerative diseases and can be studied in detail in the neuronal cell line HT22, where extracellular...
10.
Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter H, Issberner A, et al.
J Neuroinflammation
. 2012 Jul;
9:163.
PMID: 22769044
Background: Neuronal degeneration in multiple sclerosis has been linked to oxidative stress. Dimethyl fumarate is a promising novel oral therapeutic option shown to reduce disease activity and progression in patients...